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Abstract
Background: Sino-implant (II) is a two-rod subcutaneous contraceptive implant used up to 4 years, containing 150 mg of levonorgestrel. We
conducted two observational studies of Sino-implant (II) to evaluate its performance in routine service delivery settings.
Methods: We enrolled 1326 women age 18–44 who had Sino-implant (II) inserted at clinics in Pakistan and Kenya. Women were followedup using either an active or passive follow-up scheme in each study. Study outcomes were: one-year cumulative pregnancy and
discontinuation rates; rates of insertion and removal complications; adverse event and side effect rates; reasons for discontinuation; and
implant acceptability and satisfaction with clinic services.
Results: A total of 754 women returned for at least one follow-up visit. The overall Pearl pregnancy rate was 0.4 per 100 woman-years [95%
confidence interval (CI) 0.1, 0.9] resulting from 1 confirmed post-insertion pregnancy in Kenya and 4 in Pakistan. Country-specific Pearl
rates were 0.2 (95% CI 0.0, 0.9) in Kenya and 0.6 (95% CI 0.2, 1.6) in Pakistan. The total cumulative 12-month probability of removal was
7.6% (95% CI 6.1, 9.1), with country-specific removal probabilities of 3.7% in Kenya (95% CI 2.1, 5.3) and 10.8% in Pakistan (95% CI 8.5,
13.2). Four serious adverse events occurred in Kenya and none occurred in Pakistan; one SAE (an ectopic pregnancy) was possibly related to
Sino-implant (II). Most women in both countries said they would recommend the implant to others.
Conclusion: The results from these studies reveal high effectiveness and favorable safety and acceptability during the first year of use of
Sino-implant.
Implication: The favorable Sino-implant (II) findings from Kenya and Pakistan provide further evidence from disparate regions that Sinoimplant (II) is safe, effective and acceptable during routine service delivery.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.
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1. Introduction
Sino-implant (II) is a two-rod subcutaneous contraceptive
implant used for up to 4 years, containing 150 mg of
levonorgestrel and manufactured by Shanghai Dahua
Pharmaceutical. It is currently registered in 25 countries
with registration efforts underway in several others. The
implant is sold under several trade names including Zarin,
Femplant, Trust and Simplant.

0010-7824 © 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.
http://dx.doi.org/10.1016/j.contraception.2013.11.002
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A systematic review of four randomized trials of Sinoimplant (II), all conducted in China, showed first-year
pregnancy probabilities ranged between 0 and 0.1% and 4year cumulative pregnancy probabilities were 1% [1]. These
findings were followed by a recent study conducted in
Madagascar which had a one-year pregnancy rate of 0 and a
cumulative one-year discontinuation probability of 7.6% [2],
providing further evidence of the method’s effectiveness,
safety and acceptability outside Asia. In tandem with the
study in Madagascar, we conducted two observational
studies of Sino-implant (II) in Kenya and Pakistan to generate
more data on the clinical performance of the method outside
of China as well as in various service delivery settings.
2. Materials and methods
2.1. Study design
We conducted two prospective observational studies under
separate but similar protocols between July 2011 and February
2013 in Kenya and Pakistan, countries where Sino-implant (II)
has been registered since 2008 and 2010, respectively. One
study was conducted at three public clinics on the periphery of
Nairobi, Kenya; the other study was conducted in clinics in
two provinces of Pakistan (Sindh and Punjab) including six
government clinics from the Population Welfare Department
in Sindh and 13 Marie Stopes Society (MSS) clinics in both
provinces. The protocols were approved by the FHI 360
Protection of Human Subjects Committee and the respective
in-country IRBs: that of the Kenya Medical Research Institute
and the National Bioethics Committee in Pakistan.
The goal of these studies was to evaluate effectiveness,
safety and acceptability of Sino-implant (II) during the first
year of use. Study outcomes were one-year cumulative
pregnancy and discontinuation rates; rates of insertion and
removal complications; side effects; serious adverse events;
reasons for discontinuation; implant acceptability and
satisfaction with clinic services.
In each study we planned to enroll approximately 600
women aged 18–44 who chose to use Sino-implant (II) and
who met clinic eligibility criteria for the method. Prior to study
enrollment, participants were provided study details and
signed an informed consent, underwent pregnancy screening
via a pregnancy checklist, and had implants inserted by trained
nurses in Kenya and physicians in Pakistan. Due to budgetary
constraints, the studies scheduled active follow-up of half of
the participants, while the other half were assigned to a passive
surveillance cohort with no scheduled follow-up visits. In
Kenya, individual participants were randomly assigned to the
active or the passive cohort. In Pakistan, clinics were randomly
assigned to conduct active or passive follow-up, stratified by
type of clinic (government or MSS) and client volume to
achieve rough balance in participant numbers. In both
countries, participants in the active cohort were asked to
return for 3- and 12-month follow-up visits, while women in
the passive cohort were asked to return only if they suspected

pregnancy, had medical problems or implant complications, or
decided to remove the implant.
2.2. Study settings
Though we did not collect data on religion, the majority
of Kenyans near the Nairobi clinics are Christian Kikuyu.
Two of the clinics were peri-urban while the third was
located in a more rural area. All three clinics offered a choice
of free long-acting contraceptive methods including Sinoimplant (II), Jadelle and IUCDs.
Nearly all women in Pakistan are Muslim and we presume
that our study participants were predominantly Muslim from
urban or peri-urban areas. The government clinics involved in
this study provided a full range of contraceptive methods gratis.
The MSS study clinics provided Sino-implant (II) free to study
participants, but charged a nominal fee for other methods.
2.3. Data collection
After obtaining written informed consent, trained study
staff comprising nurses, research assistants and counselors
confirmed study eligibility, collected demographic information and contraceptive and medical histories, and recorded
information about implant insertion based on clinic notes and
participant responses. At each follow-up visit, study staff
measured weight and blood pressure and collected selfreported information on pregnancy, side effects, continuation status, and acceptability. Nurses removed implants when
requested and recorded reasons for removal and removal
complications. At 12-month visits or whenever indicated,
urine pregnancy tests were performed.
Data were captured on paper forms during in-person visits
or telephone interviews. The sites double-entered data in
EpiData 3.1.
2.4. Statistical analyses
We estimated that enrolling 300 women in the active
cohort for each study, with loss to follow-up at 12 months
less than 20% and the true 12-month cumulative probability
of pregnancy no more than 1%, would provide 90% chance
of ruling out a 4.5% pregnancy probability (i.e. obtaining an
upper 95% confidence bound of less than 4.5%) and
obtaining an estimated one-year pregnancy probability of
less than 2% [1]. We calculated Pearl pregnancy rates
(number of confirmed post-insertion pregnancies divided by
the total woman-years of observation). We used life table
methods to calculate the cumulative probability of implant
removal. Women in the active cohort were censored at the
time of implant removal or the time of their last clinic visit,
whichever was first; women in the passive cohort were
censored 12-months post-insertion or earlier if they returned
spontaneously to remove an implant. Women who did not
have any clinical indication of pregnancy were considered
not pregnant through the time of their last clinic visit for the
active cohort; or through the 12-month follow-up period if
not censored earlier for the passive cohort.
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Although only half the women were scheduled for
follow-up, a number of women in the passive cohort
returned for one or more clinic visits. We present the
combined effectiveness, safety and acceptability data for all
study participants regardless of cohort. We consider this
combined analysis our primary analysis utilizing the most
complete set of data. However, we conducted sensitivity
analyses to check the robustness of the findings. First, to
eliminate any unmeasured source of bias when presenting
the combined cohort data, we present the Pearl rate and the
removal probability for the active cohorts only. Second, we
censored women at the date of pregnancy, implant
removal, or last study visit, which would remove persontime from the denominator from unobserved women in the
passive cohort.
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Many of the questionnaire items were asked at multiple
follow-up visits (side effects, acceptability items), so we
refer to those responses as “ever” reported.

3. Results
We enrolled 1326 women (Fig. 1) between the two
studies, with 602 in Kenya (300 active cohort; 302 passive
cohort) and 724 in Pakistan (392 active cohort; 332 passive
cohort). The mean age of enrolled women was 28 in both
studies (Table 1). The mean weight of study participants was
62 kg in Kenya and 54 kg in Pakistan. All enrolled women in
Pakistan and most in Kenya were married. Ninety-one
percent of women in Pakistan and 41% in Kenya were

Fig. 1. Participant Flow Diagram.
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Table 1
Select sociodemographic, obstetric and contraceptive characteristics of participants

Age (years)
18–24
25–29
30–34
N34
Mean (SD)
Median (range)
Marital status
Single
Married/living in couple
Widowed/divorced/separated
Education level
Did not complete primary
Completed primary
Completed secondary/vocational/technical/higher
Occupation
Unemployed/housewife
Employed outside the home
Gravidity
Mean (SD)
Median (range)
Parity
Mean (SD)
Median (range)
Contraceptive method prior to study
None
Oral
Condom
Injectable
IUCD
Implant
Other

Pakistan (N=724)

Kenya (N=602)

Total (N=1326)

n (%)

n (%)

n (%)

133 (18.4)
261 (36.0)
217 (30.0)
113 (15.6)
28.6 (4.8)
28 (18 to 41)

201 (33.4)
177 (29.4)
135 (22.4)
89 (14.8)
28.0 (5.8)
27 (18 to 44)

334 (25.2)
438 (33.0)
352 (26.5)
202 (15.3)
28.3 (5.3)
28 (18 to 44)

0 (0.0)
724 (100)
0 (0.0)

40 (6.6)
531 (88.2)
31 (5.1)

40 (3.0)
1255 (94.6)
31 (2.4)

318 (43.9)
172 (23.8)
234 (32.3)

47 (7.8)
357 (59.3)
198 (32.9)

365 (27.5)
529 (39.9)
432 (32.6)

656 (90.6)
68 (9.5)

247 (41.0)
355 (59.0)

903 (68.1)
423 (31.9)

4.3 (2.3)
4 (1 to 20)

2.5 (1.3)
2 (0 to 8)

3.5 (2.1)
3 (0 to 20)

3.7 (2.0)
3 (0 to 20)

2.4 (1.2)
2 (1 to 8)

3.1 (1.8)
3 (0 to 20)

445 (61.5)
43 (5.9)
108 (14.9)
79 (10.9)
23 (3.2)
0 (0.0)
26 (3.6)

112 (18.6)
228 (37.9)
14 (2.3)
151 (25.1)
2 (0.3)
20 (3.3)
75 (12.5)

557 (42.0)
271 (20.4)
122 (9.2)
230 (17.3)
25 (1.9)
20 (1.5)
101 (7.6)

unemployed/housewives. One third of women in both
countries had completed secondary school or higher.
Among the Kenyan cohort, oral contraceptive pills were
the most common family planning method recently used at
enrollment (38%) followed by injectables (25%). In
Pakistan, most (62%) women reported currently using no
contraceptive method at baseline (Table 1). In Kenya, the
median number of previous pregnancies and births were both
2, while the number was higher in Pakistan with a median
gravidity of 4 and median parity of 3.
Reports of satisfaction with clinic services and the
implant insertion procedures were very high in both studies
with nearly all women reporting an overall satisfactory
experience at enrollment. One insertion complication was
reported in Kenya and 7 were reported in Pakistan, mostly
involving pain during the procedure.

3.1. Primary analysis
Between the active and passive cohorts, 754 women
returned for at least one follow-up visit (311 in Kenya and

443 in Pakistan; Fig. 1). Of women in the active cohorts, 31/
300 in Kenya (10%) and 9/392 in Pakistan (2%) were lost to
follow-up. The overall Pearl rate was 0.4 per 100 womanyears (95% confidence interval [CI] 0.1, 0.9) resulting from
1 post-insertion pregnancy in Kenya and 4 in Pakistan.
Country-specific Pearl rates were 0.2 (95% CI 0.0, 0.9) in
Kenya and 0.6 (95% CI 0.2, 1.6) in Pakistan. No serious
adverse events (SAEs) occurred in Pakistan and 4 occurred
in Kenya; one of these SAEs (an ectopic pregnancy) was
possibly related to Sino-implant (II).
Twenty-three Kenyan women and 77 Pakistani women
had implants removed, making the total 12-month cumulative probability of removal 7.6% (95% CI 6.1, 9.1), with
country-specific removal probabilities of 3.7% in Kenya
(95% CI 2.1, 5.3) and 10.8% in Pakistan (95% CI 8.5, 13.2).
Two removal complications (pain) were reported, both in
Pakistan. Most of the women who removed implants did so
for vaginal bleeding abnormalities and a variety of other
medical and personal reasons (Table 2). The most common
side effect reported in both countries was headache (6.1% in
Kenya and 36.6% in Pakistan; Table 2). Other side effects
included mood changes (1.0% in Kenya and 18.1% in

A. Lendvay et al. / Contraception 89 (2014) 197–203
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Table 2
Side effects and removal reasons reported during follow-up

Ever noticed physical or mental health changes since implant insertion
None c
Headaches
Weight gain
Weight loss
Hair loss c
Acne
Mood changes
Arm pain or numbness
Other
Total women with 1 or more follow-up visits
Why did you have implant removed a,d
Irregular, prolonged or heavy bleeding
Became pregnant e
Spontaneous expulsion
Other medical reason
Family opposition
Wanted to get pregnant
Other personal reasons
Total women with implant removal
a
b
c
d
e

Pakistan

Kenya

Total

n (%)

n (%)

n (%)

162 (36.6)
52 (11.7)
2 (0.5)
34 (7.7)
16 (3.6)
80 (18.1)
12 (2.7)
89 (20.1)
443

250 (80.4)
19 (6.1)
12 (3.9)
12 (3.9)
3 (1.0)
3 (1.0)
5 (1.6)
16 (5.1)
311

250 (33.2)
181 (24.0)
64 (8.5)
14 (1.9)
34 (4.5)
19 (2.5)
83 (11.0)
17 (2.3)
105 (13.9)
754

27 (35.1)
3 (3.9)
2 (2.6)
28 (36.4)
10 (13.0)
8 (10.4)
1 (1.3)
77

5 (21.7)
3 (13.0)
3 (13.0)
8 (34.8)
2 (8.7)
4 (17.4)
2 (8.7)
23

32 (32.0)
6 (6.0)
5 (5.0)
36 (36.0)
12 (12.0)
12 (12.0)
3 (3.0)
100

a,b

More than one response possible.
The denominator includes all women who returned for at least 1 follow-up visit.
“None” was not a response choice in Pakistan. “Hair loss” was not a response choice in Kenya.
The denominator includes all women who reported implant removal during follow-up.
In Kenya, two women who had implants removed were pregnant before implant insertion. Therefore, these two women are not included in the pregnancy
analysis.

Pakistan), weight gain (3.9% Kenya and 11.7% Pakistan),
and hair loss (7.7% Pakistan only).
Bleeding patterns were generally acceptable with 290/311
(93%) Kenyan participants and 325/443 (73%) Pakistani
participants ever reporting acceptable bleeding patterns
during follow-up. Of the 311 Kenyan women who reported
their experience with the implant, 137 (94%) ever reported
having a very favorable experience with the implant during
follow-up (Table 3). The rate was somewhat lower in
Pakistan with 31% of women ever reporting very favorable
experience and 75% ever reporting a somewhat favorable
experience. In Kenya, 9 out of 10 women ever reported that
there was nothing they disliked about the implant, whereas in
Pakistan less than half the women reported disliking nothing
about the implant. In both studies, the most common dislike
ever reported was menstrual changes (18% in Kenya and
67% in Pakistan). In Kenya, almost all women said they
would definitely recommend the implant to a friend whereas
in Pakistan the number was slightly less with four fifths of
women reporting that they would definitely recommend it to
a friend.
3.2. Sensitivity analyses
When considering the active cohorts only, four pregnancies occurred in the active cohort, all in Pakistan. The twocountry combined Pearl rate for women in the active cohort
was 0.6 (95% CI 0.2, 1.6). The country-specific Pearl rates in

the active cohorts were as follows: Kenya 0.0 (95% CI 0.0,
1.3) and Pakistan 1.2 (95% CI 0.3, 3.0).
Again considering only women in the active cohorts, 21
of 300 Kenyan women and 49 of 392 Pakistani women had
implants removed, making the total 12-month cumulative
probability of removal 10.7% (95% CI 8.2, 13.1%), with
country-specific removal probabilities of 7.1% in Kenya
(95% CI 4.1, 10.2%) and 13.4% in Pakistan (95% CI 9.6,
17.3%).
When we used an alternative analysis approach and
removed the contribution of person-time from women in the
passive cohort who did not return for any follow up visits,
the combined (both countries, both cohorts) Pearl rate was
0.8 (95% CI 0.3, 1.9), about double our primary estimate.

4. Discussion
Until now, the vast majority of data on Sino-implant (II)
comes from China [1]. As Sino-implant (II) becomes
available in additional countries, gathering broader data on
its effectiveness, safety and acceptability is imperative.
These studies from Kenya and Pakistan showed that the
Sino-implant (II) was safe and effective as delivered through
routine health services during the first year of use, with 12month pregnancy rates below 1% in both countries. Selfreported acceptability as well as continuation rates in both
countries were generally high, though notably higher in
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Table 3
Self-reported implant acceptability by women who returned for at least 1 follow-up Visit
Pakistan

Kenya

Total

(N=443) (%)

(N=311) (%)

(N=754) (%)

137 (30.9)
331 (74.7)
95 (21.4)
20 (4.5)
10 (2.3)

292 (93.9)
32 (10.3)
1 (0.3)
14 (4.5)
4 (1.3)

429 (56.9)
363 (48.1)
96 (12.7)
34 (4.5)
14 (1.9)

298 (67.3)
27 (6.1)
3 (0.7)
46 (10.4)
4 (0.9)
200 (45.1)
23 (5.2)

55 (17.7)
14 (4.5)
0 (0.0)
7 (2.3)
0 (0.0)
281 (90.4)
12 (3.9)

353 (46.8)
41 (5.4)
3 (0.4)
53 (7.0)
4 (0.5)
481 (63.8)
35 (4.6)

338 (76.3)
99 (22.3)
49 (11.1)
25 (5.6)
28 (6.3)
1 (0.2)

144 (46.3)
203 (65.3)
89 (28.6)
165 (53.1)
7 (2.3)
13 (4.2)

482 (63.9)
302 (40.1)
138 (18.3)
190 (25.2)
35 (4.6)
14 (1.9)

27 (6.1)
19 (4.3)
174 (39.3)
364 (82.2)

1 (0.3)
1 (0.3)
19 (6.1)
300 (96.5)

28 (3.7)
20 (2.7)
193 (25.6)
664 (88.1)

a

Overall experience with implant
Very favourable
Somewhat favourable
Indifferent
Somewhat unfavourable
Very unfavourable
Disliked about implant a
Menstrual changes
Other side effects
Appearance
Way it feels
Insertion procedure
Nothing
Other
Liked about implant a
Lasts for 4 years
Easy to use
Low risk for pregnancy
Few side effects
Nothing
Other
Would recommend implant method to a friend a
Definitely not
Probably not
Probably yes
Definitely yes
a

More than one response possible. Responses were captured across visits.

Kenya than Pakistan. However, the one-year continuation
rate observed in Pakistan was similar to the one-year
Norplant continuation rate in a previous study in Pakistan
[3] and also similar to the overall one-year continuation rate
found during clinical trials of Jadelle conducted in several
countries [4]. Furthermore, data from other hormonal
implant studies indicate that women in Pakistan typically
have lower 1-year continuation rates than other countries
studied [3,5,6].
The sole pregnancy observed in Kenya was ectopic
reported 14 months after implant insertion, with an uncertain
estimated date of conception. We included four postinsertion pregnancies from Pakistan in our Pearl rate
calculations. This group included two pregnancies that
may have pre-dated enrollment or occurred as a result of the
women not using a back-up contraceptive method immediately after implant insertion, despite having menstruation
more than 7 days before insertion.
A major strength of both studies was the very high
retention rate for participants in the active follow-up cohorts,
yielding substantial person-years of observation. Also, by
collecting data from two countries with differing clientele,
we captured country-specific response patterns in regards to
perceived side effects and acceptability of the method. The
higher rates of reported side effects in Pakistan, lower
acceptability of bleeding patterns, and higher removal rates

there may be influenced by an array of cultural, religious, or
economic factors that were not explored in our studies. Prior
contraceptive experience may have played a role in women’s
attitudes towards the implant. In Kenya, a large portion of
women who enrolled in the study had recently used a
hormonal contraceptive method. In contrast, most women in
Pakistan had not been using a hormonal method prior to
enrollment, potentially magnifying the impact of bleeding
disturbances and other side effects associated with the
hormonal contraceptive methods.
Inherent in our studies were two design limitations. First
and foremost, only half of study participants were actively
followed through 12 months, as women in the passive group
only returned at their own prompting. This financially-driven
feature had multiple ramifications. We were unable to assign
an end-of-study status to most women in the passive cohorts.
Since women had other options for care in these areas, and
those unhappy with the method could have attended other
clinics, we probably missed side effects and removals. Most
importantly, we may have missed an unknowable number of
pregnancies. Using a more conservative estimate of the
follow-up time contributed by women in the passive cohorts,
the estimate of the pregnancy rate about doubled. Further
restricting the analysis to women in the active follow-up
cohort only yielded a Pearl rate that was intermediate. The
upper bound of the 95% CIs in our primary and sensitivity
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analyses were consistently below 2%. These analyses
provide evidence of high effectiveness.
The second main limitation is the one-year follow-up
period. Sino-implant (II) is approved for four years of use,
and our study outcomes should be measured over that entire
interval. Still, the favorable findings from both countries
provide further evidence from disparate regions that Sinoimplant (II) is safe, effective and acceptable during routine
service delivery. Further research studies should incorporate
active follow-up of all participants in order to provide more
precise and accurate pregnancy and continuation estimates.
Longer follow-up of Sino-implant (II) users should also
be done to collect effectiveness, safety and acceptability data
over the full 4-year period of use to inform policy makers
and providers about the potential programmatic value of
Sino Implant (II).
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